Forvisirvat
Forvisirvat is a sirtuin-6 activator which is under development for the treatment of major depressive disorder and schizophrenia. It is taken by mouth. As of January 2025, forvisirvat is in phase 2/3 clinical trials for major depressive disorder and is in phase 1/2 clinical trials for schizophrenia. It is under development by Sirtsei Pharmaceuticals and Arrivo BioVentures.